Literature DB >> 31911864

Ethical consideration and feasibility demonstration of high-intensity interval training without the use of electrical shocks in mice with and without doxorubicin exposition.

Maxime Caru1,2,3, François Lalonde1,4,5, Elise Legault4,5, Daniel Curnier1,3,4, David H St-Pierre3,5, Alain Steve Comtois5, François Tournoux4.   

Abstract

INTRODUCTION: Most protocols intended to stimulate cardiovascular training in mice use electrical shocks that cause psychological stress and interfere with running performance. The aim of this study was to: 1) demonstrate the feasibility of a two-week high-intensity interval training (HIIT) program without the use of electric shocks in mice and 2) show that HIIT without electric shocks is feasible in the specific context of mice exposed to chemotherapy (i.e., doxorubicin).
METHODS: Ten C57bl/6 6-week-old female mice underwent a maximal exercise capacity test before and after two weeks of HIIT (five sessions per week) to measure their maximum running speed. The electrical stimulus was substituted by gently lifting the hind legs of the training mice using a tongue depressor. A second sample of ten C57bl/6 10-week-old female mice receiving a single intravenous injection of 20 mg/kg of doxorubicin underwent a single session of HIIT post-DOX using the same gentle stimulation method.
RESULTS: After two weeks of HIIT without the use of electric shocks, non-treated mice had a significant increase in their maximal speed (4.4 m•min-1; P = 0.019). In DOX-treated mice, the compliance rate to run went from 100% during the acclimation period prior to doxorubicin treatment to 100% when HIIT was performed after the DOX treatment. Doxorubicin treatment seemed to affect exercise compliance in DOX-treated mice. Our study demonstrated that a two-week HIIT program in non-treated mice and a single HIIT session in DOX-treated mice are feasible.
CONCLUSION: The use of electric shocks was not required to obtain acceptable exercise compliance and a significant change in mice physical capacity. Our technique to perform a treadmill maximal exercise capacity test was shown to be feasible, even in specific pathological conditions like chemotherapy infusion, and could become a reference for future research protocols aimed at reducing the impact of psychological stress caused by electric shocks in mice. This model of exercise training in mice introduces an alternative to ethical conduct standards in animal research. AJCR
Copyright © 2019.

Entities:  

Keywords:  Exercise; animal ethics; doxorubicin; exercise testing; high-intensity interval training

Year:  2019        PMID: 31911864      PMCID: PMC6943355     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  38 in total

Review 1.  Physiological adaptations to low-volume, high-intensity interval training in health and disease.

Authors:  Martin J Gibala; Jonathan P Little; Maureen J Macdonald; John A Hawley
Journal:  J Physiol       Date:  2012-01-30       Impact factor: 5.182

2.  Assessment of murine exercise endurance without the use of a shock grid: an alternative to forced exercise.

Authors:  Jennifer D Conner; Tami Wolden-Hanson; LeBris S Quinn
Journal:  J Vis Exp       Date:  2014-08-14       Impact factor: 1.355

3.  How to train a mouse-methodological issues in pre-clinical exercise oncology.

Authors:  Luma Melo; Amit Hagar
Journal:  Am J Cancer Res       Date:  2019-06-01       Impact factor: 6.166

4.  Interval versus continuous aerobic exercise training in breast cancer survivors--a pilot RCT.

Authors:  Lianne B Dolan; Kristin Campbell; Karen Gelmon; Sarah Neil-Sztramko; Daniel Holmes; Donald C McKenzie
Journal:  Support Care Cancer       Date:  2015-05-09       Impact factor: 3.603

5.  High-intensity intermittent exercise and fat loss.

Authors:  Stephen H Boutcher
Journal:  J Obes       Date:  2010-11-24

6.  Reference Equation for the Incremental Shuttle Walk Test in Children and Adolescents.

Authors:  Fernanda de Cordoba Lanza; Eduardo do Prado Zagatto; Jacksoel Cunha Silva; Jessyca Pachi Rodrigues Selman; Treice Beatriz Gonçalves Imperatori; Drielly Jésica Milani Zanatta; Luana Nascimento de Carvalho; Mariana Mazzuca Reimberg; Simone Dal Corso
Journal:  J Pediatr       Date:  2015-08-29       Impact factor: 4.406

Review 7.  Exercise Dose in Clinical Practice.

Authors:  Meagan M Wasfy; Aaron L Baggish
Journal:  Circulation       Date:  2016-06-07       Impact factor: 29.690

8.  Impact of leucine supplementation on exercise training induced anti-cardiac remodeling effect in heart failure mice.

Authors:  Wilson Max Almeida Monteiro de Moraes; Thaís Plasti Melara; Pamella Ramona Moraes de Souza; Fabiana de Salvi Guimarães; Luiz Henrique Marchesi Bozi; Patricia Chakur Brum; Alessandra Medeiros
Journal:  Nutrients       Date:  2015-05-15       Impact factor: 5.717

9.  Graded Maximal Exercise Testing to Assess Mouse Cardio-Metabolic Phenotypes.

Authors:  Jennifer M Petrosino; Valerie J Heiss; Santosh K Maurya; Anuradha Kalyanasundaram; Muthu Periasamy; Richard A LaFountain; Jacob M Wilson; Orlando P Simonetti; Ouliana Ziouzenkova
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

10.  Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.

Authors:  Sara Mijwel; Malin Backman; Kate A Bolam; Anna Jervaeus; Carl Johan Sundberg; Sara Margolin; Maria Browall; Helene Rundqvist; Yvonne Wengström
Journal:  Breast Cancer Res Treat       Date:  2017-11-14       Impact factor: 4.872

View more
  1 in total

1.  Daily running enhances molecular and physiological circadian rhythms in skeletal muscle.

Authors:  Nuria Casanova-Vallve; Drew Duglan; Megan E Vaughan; Marie Pariollaud; Michal K Handzlik; Weiwei Fan; Ruth T Yu; Christopher Liddle; Michael Downes; Julien Delezie; Rebecca Mello; Alanna B Chan; Pål O Westermark; Christian M Metallo; Ronald M Evans; Katja A Lamia
Journal:  Mol Metab       Date:  2022-04-22       Impact factor: 8.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.